Last $656.80 MXN
Change Today 0.00 / 0.00%
Volume 0.0
ABT* On Other Exchanges
Symbol
Exchange
New York
Mexico
SIX Swiss Ex
London
Sao Paulo
Frankfurt
As of 4:08 PM 12/11/14 All times are local (Market data is delayed by at least 15 minutes).

abbott laboratories (ABT*) Snapshot

Open
$656.80
Previous Close
$656.80
Day High
$656.80
Day Low
$656.80
52 Week High
12/11/14 - $656.80
52 Week Low
01/24/14 - $475.00
Market Cap
989.0B
Average Volume 10 Days
271.0
EPS TTM
--
Shares Outstanding
1.5B
EX-Date
01/13/15
P/E TM
--
Dividend
$0.96
Dividend Yield
1.76%
Current Stock Chart for ABBOTT LABORATORIES (ABT*)

abbott laboratories (ABT*) Details

Abbott Laboratories manufactures and sells health care products worldwide. Its Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome, intrahepatic cholestasis or depressive symptoms, gynecological disorders, dyslipidemia, hypertension, hypothyroidism, pain, fever, and inflammation; and regulates physiological rhythm of the colon, as well as provides hormone replacement therapy and anti-infective and influenza vaccines. The company’s Diagnostic Products segment provides diagnostic systems and tests, such as immunoassay and clinical chemistry systems; assays for screening and diagnosis for drugs of abuse, cancer, therapeutic drug monitoring, fertility, and physiological and infectious diseases; hematology systems and reagents; genomic-based tests; informatics and automation solutions; and diagnostic systems and tests for blood analysis, as well as instruments that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents. Its Nutritional Products segment offers pediatric and adult nutritional products, such as various forms of prepared infant and follow-on formula. The company’s Vascular Products segment provides coronary, endovascular, vessel closure, and structural heart devices for the treatment of vascular diseases. Abbott Laboratories also offers blood glucose and glucose monitoring systems, test strips, and data management software and accessories for people with diabetes; and medical devices for the eye, such as cataract surgery, LASIK surgery, and contact lens care and dry eye products. The company primarily serves retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices, and government agencies. It has strategic alliance with Fonterra Co-operative Group Ltd. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.

69,000 Employees
Last Reported Date: 02/21/14
Founded in 1888

abbott laboratories (ABT*) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.9M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $969.7K
Executive Vice President, General Counsel and...
Total Annual Compensation: $650.0K
Executive Vice President of Diagnostic Produc...
Total Annual Compensation: $614.6K
Executive Vice President of Corporate Develop...
Total Annual Compensation: $629.5K
Compensation as of Fiscal Year 2013.

abbott laboratories (ABT*) Key Developments

Abbott Announces Quarterly Cash Dividend, Payable on Feb. 13, 2015

The board of directors of Abbott increased the company's quarterly common dividend to $0.24 per share from $0.22 per share. The cash dividend is payable on Feb. 13, 2015, to shareholders of record at the close of business on Jan. 15, 2015.

Abbott Announces Availability its Innovative Diagnostic Platform, IRIDICA in Europe and Other CE-Mark Recognized Countries

Abbott announced its innovative diagnostic platform, known as IRIDICA, is now available in Europe and other CE-Mark recognized countries. The new platform can identify more than 1,000 infection-causing pathogens in less than six hours, versus the current standard of care (culture-based testing), which can take days. By identifying the cause of infections such as bacteria, viruses or fungi sooner, doctors can improve care for the critically ill. IRIDICA uses a combination of sophisticated testing technologies known as Polymerase Chain Reaction/Electrospray Ionization Mass Spectrometry (PCR/ESI-MS) to rapidly identify infection-causing pathogens directly from a patient's sample, without the need for culture. According to its RApid Diagnosis of Infections in the CriticAlly IlL (RADICAL) study results, the technology was able to detect pathogens when the current standard of care did not. In the study, after retrospectively comparing the results of Abbott's technology versus culture, an independent panel of physicians reported it would have prescribed a different course of treatment in nearly 60% of cases evaluated. Additionally, analysis of the study results suggested that its technology could help lower associated health care costs by 30% and reduce hospital stays for people with serious infections by up to eight days. IRIDICA also represents a step forward in the effort to combat the overuse of antibiotics. According to the World Health Organization (WHO), the overuse and misuse of antibiotics have driven the rise of antibacterial resistance, which is considered an increasingly serious threat to public health. IRIDICA currently offers five testing panels for pathogens that cause infections in the critically ill such as sepsis; other bacterial, fungal and viral infections; and ventilator-associated pneumonia.

Abbott Laboratories Announces Unaudited Consolidated Earnings Results for Third Quarter and Nine Months Ended September 30, 2014 ; Revises Earnings Guidance for the Full Year 2014 ; Provides Earnings Guidance for the Fourth Quarter of 2014

Abbott Laboratories announced unaudited consolidated earnings results for third quarter and nine months ended September 30, 2014. For the quarter, the company reported net sales of $5,104 million, operating earnings of $731 million, earnings from continuing operations before taxes of $718 million, earnings from continuing operations of $440 million or $0.29 per diluted share, net earnings of $538 million or $0.36 per diluted share compared to the net sales of $4,825 million, operating earnings of $473 million, earnings from continuing operations before taxes of $481 million, earnings from continuing operations of $644 million or $0.41 per diluted share, net earnings of $966 million or $0.61 per diluted share for the same quarter a year ago. For the year to date, the company reported net sales of $14,957 million, operating earnings of $1,772 million, earnings from continuing operations before taxes of $1,716 million, earnings from continuing operations of $1,089 million 0 of $0.71 per diluted share, net earnings of $1,380 million 0 of $0.9 per diluted share compared to the net sales of $14,643 million, operating earnings of $1,505 million, earnings from continuing operations before taxes of $1,433 million, earnings from continuing operations of $1,504 million 0 of $0.95 per diluted share, net earnings of $1,987 million 0 of $1.25 per diluted share for the same period a year ago. The company is raising the mid-point and narrowing its full-year 2014 earnings-per-share guidance, excluding specified items, to $2.25 to $2.27 from $2.19 to $2.29, representing double-digit growth. This guidance includes results from the developed markets branded generics pharmaceuticals business, reported as discontinued operations due to the pending sale of this business to Mylan. Projected full-year 2014 EPS under GAAP is $1.22 to $1.24. The company fourth-quarter 2014 earnings-per-share guidance, excluding specified items, of $0.68 to $0.70, representing double-digit growth. Abbott forecasts specified items for the fourth quarter 2014 of $0.36. Including specified items, projected earnings-per-share under GAAP would be $0.32 to $0.34 for the fourth quarter. This guidance includes results from both continuing and discontinued operations.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABT*:MM $656.80 MXN 0.00

ABT* Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $67.71 USD -0.21
Actavis plc $265.39 USD +1.64
Eli Lilly & Co $72.40 USD -0.05
General Mills Inc $53.81 USD +0.30
Novo Nordisk A/S kr266.00 DKK -0.50
View Industry Companies
 

Industry Analysis

ABT*

Industry Average

Valuation ABT* Industry Range
Price/Earnings 36.2x
Price/Sales 3.1x
Price/Book 3.0x
Price/Cash Flow 25.6x
TEV/Sales 2.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ABBOTT LABORATORIES, please visit www.abbott.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.